Geron Corp (GERN)

[Joda]

There is some definitely interesting things brewing here, at least that is what I am seeing and feeling...

The MM's have been trying to get the price down below $4.00 so the options expire, at least that is my understanding (not a trader really)...
...and they do not seem to be able to hold it down.

I get the feeling that as time goes, the manipulators are losing control of the PPS action.

Plus there just seems to be too much smoke coming up, and they do not seem in any need to share the information.
To me this denotes great confidence, and that this is for real.

When things are big like this, you are very cautious not to screw it up...

Some other little tidbits I am getting from other boards as well;

---------------------------------------------------------------

grn163L is able to return some patients to health in some cancers (i.e., MF, AML, ET, PV, etc.)

it has been shown by the mayo clinic when administering grn163L that some patients' cancers go into remission.

the next step for imetelstat is FDA approval and to achieve this dr scarlett has signed on with jNj.

janssen will be able to ascertain the gene mutation(s) common to a basket of cancers in which grn163L is effective.

so ... in the not too distant future, some cancers will yield a rather large sum of cash to GERN investors!

-------------------------------------------------------------------

"(grn163L) works on some patients." this statement is true.

the above quoted statement is true because NOT ALL patients' cancers involve the same gene mutation(s). so, even though a group of patients may be diagnosed with the same cancer (i.e., MF) the underlying mutation(s) that caused their MF may not involve (and probably will not involve) the same mutation(s).

identifying the mutation(s) in which grn163L is efficacious is key and this is why chip signed on with jNj because johnson & johnson has the resources to do just that—to find those mutations that will allow grn163L to become a pan cancer drug.

what this means is that grn163L will work on a "basket" of cancers with the same mutation(s) ... NOT ALL patients with cancer.

---------------------------------------------------------------------

if grn163L works...and the mayo says it does.

then we're looking at a pan cancer drug that will be applied to a "basket" of cancers based on certain gene mutations. to root out these specific mutations dr scarlett had to signup with jNj which has the money and man power to do this work. this work may take a couple of years but jNj will most likely receive FDA approval in less time.

with an FDA approved pan cancer drug geron's value will surpass pcyc's value by billions of dollars. with 157 million shares outstanding geron's share price will fetch a minimum of $150.

does it work?

the mayo says it does!

and this is why GERN will be $150/share in 2017!!!

------------------------------------------------------------------

mutations ... this is what it is all about and this is why geron had to hook up with jNj.

johnson and johnson will be able to "fine tune" the patient selection process and isolate specific "mutations" where grn163L is most efficacious.

this will result in a speedy and certain FDA approval process.

------------------------------------------------------------------

"WE PROPOSE THAT INTERPRETIVE STRATEGIES CONSIDERING BOTH CELLULAR AND GENOMIC CONTEXT OF MUTATIONS WILL PROVIDE A MORE ACCURATE RATIONALE FOR TREATMENT DECISIONS."

interpretive strategies involving cellular & genomic mutations is a where jNj's expertise will shine brightly.

-----------------------------------------------------------------------

JAMA Oncol. Published online March 12, 2015

Mutations and other somatic genomic abnormalities are commonly used to inform treatment decisions. Such molecularly based personalized treatment strategies were until recently limited to an assortment of rare tumor types or molecularly defined subtypes of common cancers.

Lately, these strategies have expanded to other tumor types, in particular lung cancer and melanoma.

Although the approach to genomic-based treatment decisions has been broadly embraced, provision of a targeted agent to a patient whose cancer harbors the genomic target rarely leads to cure, and sometimes responses are incomplete.

Also, opportunity costs for patients and the expenses of ineffective treatments are great; therefore, improvements are needed in the effective clinical use of mutation data.

Although patients do benefit from today’s approach to interpreting mutation data, WE PROPOSE THAT INTERPRETIVE STRATEGIES CONSIDERING BOTH CELLULAR AND GENOMIC CONTEXT OF MUTATIONS WILL PROVIDE A MORE ACCURATE RATIONALE FOR TREATMENT DECISIONS.

Cellular context accounts for histologic etiology and how cell type–specific differences in cellular signaling impact treatment success.

Genomic context includes 3 distinct considerations: (1) clonal diversity of cancer cell populations and resulting evolution induced by treatment, (2) the presence of resistance mutations or other genomic features that preclude effective targeting of a mutation treatment efficacy barriers), and (3) the driver or activation status of the mutation at the time of treatment.